There Might be a Risk of Anaphylaxis Due to Omalizumab (Anti-IgE) Therapy

Abstract

The most common adverse reaction from omalizumab is injection site in duration, injection site itching, injection site pain and bruising but the package insert contains warnings regarding parasitic infections. While there are no reports of fatal anaphylaxis as a result of omalizumab, some cases have been serious and potentially life-threatening. Therefore, the FDA requires that people receiving omalizumab be monitored in the physician's office for a period of time after their injections.

Advances in Anti-IgE Therapy

“…We did not stop omalizumab therapy. We do not suggest omalizumab during the first five days of complicated viral infections such as common cold and bacterial sinus infections [ 94 ].…”